TNG908 clinical trials

A Phase 1/2, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, and Preliminary Anti-tumor Activity of TNG908 in Patients with MTAP-deleted Advanced or Metastatic Solid Tumors

This study is testing a new drug, TNG908, for people with advanced cancers that have a specific genetic change called MTAP-deleted. It aims to see if the drug is safe, what dose works best, and if it can help shrink tumours.